Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.

Abstract:

:Nifedipine kinetics have not been described in clinically relevant detail because of difficulties in formulating a stable preparation for intravenous use and lack of a specific and sensitive assay for plasma nifedipine. We recently developed a gas-chromatographic method and determined conditions in which nifedipine could be protected from photodegradation. Therefore, we evaluated the kinetics and bioavailability of nifedipine in 12 normal subjects after single intravenous (1 mg/5 min) and oral (10 mg) doses. After intravenous dosing, the drug was eliminated with a half-time of 1.77 +/- 0.25 hour, and total clearance was calculated at 0.62 +/- 0.09 liter/kg/hr. With oral drug administration, the elimination half-time was twice as long for the group; but within these subjects, marked variability in the rate of appearance of the drug in plasma was observed, giving profiles consistent with fast and slow absorption. In the latter group, peak plasma drug concentrations were only one third the level seen in those exhibiting a faster absorption profile, although the extent of drug absorption (as derived from areas under the plasma level-time curves) did not vary. Bioavailability was 0.45 +/- 0.08. Untoward effects resulting from the drug's pharmaco-subjects after intravenous administration (flushing).

journal_name

J Clin Pharmacol

authors

Foster TS,Hamann SR,Richards VR,Bryant PJ,Graves DA,McAllister RG

doi

10.1002/j.1552-4604.1983.tb02720.x

subject

Has Abstract

pub_date

1983-04-01 00:00:00

pages

161-70

issue

4

eissn

0091-2700

issn

1552-4604

journal_volume

23

pub_type

杂志文章
  • Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic.

    abstract::This report describes the first evaluation in humans of Ro 41-3696. Based on its preclinical profile, Ro 41-3696, a nonbenzodiazepine partial agonist at the benzodiazepine receptor, offers promising perspectives as an innovative hypnotic drug in that it does not exhibit most of the disadvantages associated with full a...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1995.tb04126.x

    authors: Dingemanse J,Bury M,Roncari G,Zell M,Gieschke R,Gaillard AW,Odink J,van Brummelen P

    更新日期:1995-08-01 00:00:00

  • The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.

    abstract::A randomized, single-blind, placebo-controlled, parallel-group study was conducted to assess the effect of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor. Subjects (n = 34) were enrolled into four groups: young males or females (aged 18-45 years) and el...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/jcph.5

    authors: Kubitza D,Becka M,Roth A,Mueck W

    更新日期:2013-03-01 00:00:00

  • Impulsive-aggressive traits, serotonin function, and alcohol-enhanced aggression.

    abstract::Although alcohol consumption is involved in most acts of violence, most people do not become violent when they drink. Individuals also respond differently to alcohol on laboratory measures of aggression. The objective of this study was to determine whether individual differences in the effects of alcohol on a laborato...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270004270457

    authors: Fulwiler C,Eckstine J,Kalsy S

    更新日期:2005-01-01 00:00:00

  • Developmental pharmacokinetic changes of Lamivudine in infants and children.

    abstract::Lamivudine is a nucleoside reverse transcriptase inhibitor widely used in infants and children in combination antiretroviral therapy to treat human immunodeficiency virus (HIV) infection. Developmental changes in lamivudine pharmacokinetic disposition were assessed by combining data from 7 studies of lamivudine (Pedia...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/0091270011426563

    authors: Tremoulet AH,Nikanjam M,Cressey TR,Chokephaibulkit K,McKinney R,Mirochnick M,Capparelli EV

    更新日期:2012-12-01 00:00:00

  • Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion.

    abstract::The objective of this study was to assess whether cimetidine affects the pharmacokinetics of sustained-release (SR) bupropion hydrochloride and the active metabolite, hydroxybupropion. This randomized, open-label, two-period crossover study was conducted in 24 healthy volunteers 18 to 45 years of age. ANOVA showed tha...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Kustra R,Corrigan B,Dunn J,Duncan B,Hsyu PH

    更新日期:1999-11-01 00:00:00

  • Augmentation of renal citrate excretion by oral potassium citrate administration: time course, dose frequency schedule, and dose-response relationship.

    abstract::The time course, dose frequency schedule, and dose-response relationship of the citraturic response to orally administered potassium citrate was examined in 22 normal volunteers and 21 patients with uric acid or calcium nephrolithiasis. The slow-release (wax matrix) preparation of potassium citrate produced a rapid an...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1984.tb01809.x

    authors: Pak CY,Skurla C,Brinkley L,Sakhaee K

    更新日期:1984-01-01 00:00:00

  • Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes.

    abstract::The integrated glucose-insulin (IGI) model is a previously published semimechanistic model that describes plasma glucose and insulin concentrations after glucose challenges. The aim of this work was to use knowledge of physiology to improve the IGI model's description of glucose absorption and gastric emptying after t...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.602

    authors: Alskär O,Bagger JI,Røge RM,Knop FK,Karlsson MO,Vilsbøll T,Kjellsson MC

    更新日期:2016-03-01 00:00:00

  • Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain.

    abstract::The pharmacokinetic properties of dezocine were examined in 15 patients with acute or chronic pain. In 3 groups of 5 patients each, serum levels were determined at various intervals after single intravenous doses of 5, 10, and 20 mg. After these single doses, dezocine was very rapidly distributed (mean t1/2 alpha less...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1995.tb04080.x

    authors: Wilson JM,Cohen RI,Kezer EA,Schange SJ,Smith ER

    更新日期:1995-04-01 00:00:00

  • Pharmacokinetics of retinoids in women after meal consumption or vitamin A supplementation.

    abstract::These studies were conducted to evaluate the pharmacokinetics of several retinoids after meal consumption or vitamin A supplementation to establish a reference for future assessment of teratogenic risks of retinoid therapeutic agents. In the first study, 36 healthy young female volunteers consumed single meals contain...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1996.tb04253.x

    authors: Chen C,Mistry G,Jensen B,Heizmann P,Timm U,van Brummelen P,Rakhit AK

    更新日期:1996-09-01 00:00:00

  • Evaluation of Weight Thresholds for Pediatric Patients to Use Adult Dosage of Therapeutic Monoclonal Antibodies.

    abstract::With increasing interest in enrolling adolescent patients in adult trials, a question often arises: when can pediatric patients use adult dosages? For currently approved therapeutic monoclonal antibodies (mAbs) with equivalent adult and pediatric indications, body weight thresholds for pediatric patients to receive ad...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1434

    authors: Yang N,Xu MC,Yao Z

    更新日期:2019-10-01 00:00:00

  • Flow cytometric assessment of effects of fluvastatin on low-density lipoprotein receptor activity in stimulated T-lymphocytes from patients with heterozygous familial hypercholesterolemia.

    abstract::To test the effects of fluvastatin on low-density lipoprotein (LDL) receptor activity in patients with heterozygous familial hypercholesterolemia, the authors measured LDL receptor activity in stimulated T-lymphocytes prepared from 34 patients before and after treatment with 40 mg fluvastatin daily for 12 weeks. Maxim...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/00912700022009008

    authors: Raungaard B,Brorholt-Petersen JU,Jensen HK,Faergeman O

    更新日期:2000-04-01 00:00:00

  • Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.

    abstract::Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, approved for second-line therapy for advanced renal cell carcinoma (RCC). Axitinib population pharmacokinetic and pharmacokinetic/pharmacodynamic relationships were evaluated. Using nonlinear mixed effects modelin...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.73

    authors: Rini BI,Garrett M,Poland B,Dutcher JP,Rixe O,Wilding G,Stadler WM,Pithavala YK,Kim S,Tarazi J,Motzer RJ

    更新日期:2013-05-01 00:00:00

  • The pharmacokinetics and pharmacodynamics of minaxolone.

    abstract::Plasma concentrations of minaxolone were measured in 15 female patients during and for up to 3 hours after a minaxolone and nitrous oxide anesthetic. Nine patients received a single dose and six patients two or three doses of minaxolone. Plasma minaxolone decay can be described by two-compartment kinetics. Distributio...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1982.tb02681.x

    authors: Dunn GL,Morison DH,McChesney J,Pine W,Kumana CR,Gupta RN

    更新日期:1982-07-01 00:00:00

  • Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis.

    abstract::Ixekizumab (LY2439821), a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody that selectively binds and neutralizes interleukin (IL) 17A has demonstrated efficacy in the treatment of psoriasis. A population pharmacokinetics-pharmacodynamics model was developed using NONMEM 7.2 to describe the temporal re...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1002/jcph.312

    authors: Tham LS,Tang CC,Choi SL,Satterwhite JH,Cameron GS,Banerjee S

    更新日期:2014-10-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.

    abstract::Moxifloxacin is used in thorough QT studies to assess sensitivity for detection of an increase in QTc. Moxifloxacin is usually over-encapsulated for blinding. However, there is concern that over-encapsulation alters its pharmacokinetics. In a 4-arm, randomized crossover study, 22 volunteers received over-encapsulated ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270009356298

    authors: Mason JW,Florian JA Jr,Garnett CE,Moon TE,Selness DS,Spaulding RR

    更新日期:2010-11-01 00:00:00

  • The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.

    abstract::The disposition of nalmefene, an opioid antagonist intended for the reversal of opioid-induced respiratory depression, and its primary metabolite nalmefene glucuronide, were characterized in adult volunteers with normal renal function and in patients with end-stage renal disease (ESRD). The effect of hemodialysis on t...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1996.tb04179.x

    authors: Matzke GR,Frye RF,Alexander AC,Reynolds R,Dixon R,Johnston J,Rault RM

    更新日期:1996-02-01 00:00:00

  • Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow.

    abstract::The impact of a microgravity simulation using a head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as a probe to evaluate hepatic blood flow is discussed. Eight healthy male subjects were selected for a 7-day study, including a 4-day head-down tilt from day 2 to day 5. Subjects were given 1 mg/kg of lidoca...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1995.tb04110.x

    authors: Saivin S,Pavy-Le Traon A,Cornac A,Güell A,Houin G

    更新日期:1995-07-01 00:00:00

  • Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial.

    abstract::We compared the gastrointestinal (GI) tolerability and assessed for bioequivalent absorption of R-lipoic acid (LA) in people with progressive multiple sclerosis (MS) in a single-center, double-blind, randomized crossover trial. Participants randomly assigned to formulation sequence took 600 mg of R-LA or 1200 mg of a ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1605

    authors: Cameron M,Taylor C,Lapidus J,Ramsey K,Koop D,Spain R

    更新日期:2020-08-01 00:00:00

  • Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.

    abstract::The pharmacokinetics, pharmacodynamics, and safety of fosinopril sodium (SQ 28,555), a new orally active angiotensin-converting enzyme (ACE) inhibitor, was evaluated in 73 healthy men in two separate studies. In study I, doses ranging from 10 to 640 mg were administered once daily for 3 days to seven groups of five su...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1991.tb01887.x

    authors: Duchin KL,Waclawski AP,Tu JI,Manning J,Frantz M,Willard DA

    更新日期:1991-01-01 00:00:00

  • Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow.

    abstract::The interactive effects of the coadministration of steady-state cimetidine and single-dose pentopril, an angiotensin converting enzyme inhibitor, on the pharmacokinetic disposition of each other were studied in humans. Cimetidine reduced the clearance of pentopril by 11 to 14%. This reduction in clearance was shown to...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1988.tb03136.x

    authors: Kochak GM,Rakhit A,Thompson TN,Hurley ME

    更新日期:1988-03-01 00:00:00

  • Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances.

    abstract::The effects of labetalol, diltiazem and verapamil on antipyrine and indocyanine green clearance were evaluated in a placebo-controlled, repeated measures evaluation. Twelve healthy subjects received either labetalol (200 mg every 12 hours), diltiazem (90 mg. every 8 hours), verapamil (80 mg every 8 hours), or placebo ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1989.tb03250.x

    authors: Rocci ML Jr,Vlasses PH,Lener ME,Fruncillo RA,Sirgo MA

    更新日期:1989-10-01 00:00:00

  • Tissue penetration of cefpodoxime and cefixime in healthy subjects.

    abstract::Microdialysis is a technique that allows the measurement of free antibiotic concentrations in different tissues, which are responsible for the antibacterial activity at the infection site. In an open, randomized, 2-way crossover study in healthy volunteers, the muscle penetration of orally administered cefpodoxime (40...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/0091270004273679

    authors: Liu P,Müller M,Grant M,Obermann B,Derendorf H

    更新日期:2005-05-01 00:00:00

  • Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?

    abstract::Understanding how inhibition of cytochrome P4503A (CYP3A) affects the metabolism of a new drug is critical in determining if a clinically relevant drug interaction will occur. Diltiazem interaction studies assess a given compound's sensitivity to moderate CYP3A inhibition. The present study compared the effect differe...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270010387141

    authors: Friedman EJ,Fraser IP,Wang YH,Bergman AJ,Li CC,Larson PJ,Chodakewitz J,Wagner JA,Stoch SA

    更新日期:2011-11-01 00:00:00

  • A double-blind evaluation of the nocturnal antisecretory effects of anisotropine methylbromide in man. Dose response and duration of action studies.

    abstract::The effects of graded doses of anisotropine methylbromide on nocturanl gastric secretion were investigated in a double-blind crossover study in man. Single doses considerably higher than those usually employed for daytime use in adjunctive therapy of peptic ulcer disease significantly reduced acid secretion without si...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1977.tb04583.x

    authors: Freston JW,Forbes JA

    更新日期:1977-01-01 00:00:00

  • Long-term captopril in young and old patients with mild hypertension.

    abstract::The decrease in renal blood flow (RBF) observed in patients with hypertension can be increased with converting enzyme inhibition (CEI). It is unknown whether the decrease in RBF observed with age can also be increased with CEI. This study compared the short- and long-term effects of captopril monotherapy in young (les...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1991.tb01888.x

    authors: Penner SB,Mitenko PA,Aoki FY,Sitar DS,Smyth DD,McKenzie JK

    更新日期:1991-01-01 00:00:00

  • PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia.

    abstract::Current guidelines for hypercholesterolemia treatment emphasize lifestyle modification and lipid-modifying therapy to reduce the risk for cardiovascular disease. Statins are the primary class of agents used for the treatment of hypercholesterolemia. Although statins are effective for many patients, they fail to achiev...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/jcph.766

    authors: Ito MK,Santos RD

    更新日期:2017-01-01 00:00:00

  • Long-term captopril therapy: evolving hemodynamic effects.

    abstract::Nine patients with resistant hypertension received captopril for 12 months. Five received captopril alone, four required additional therapy. In the former, mean blood pressure fell from 109 +/- 4.2 mm Hg to 84 +/- 7.5 mm Hg (P less than 0.025) after seven days. A rise to 101 +/- 19 mm Hg was noted at six and 12 months...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1982.tb02634.x

    authors: Sullivan JM,Taylor JC,Patrick DR,Johnson JG,Ratts TE,Muirhead EE

    更新日期:1982-10-01 00:00:00

  • Slow-release furosemide and hydrochlorothiazide in congestive cardiac failure: a controlled trial.

    abstract::Thirty-eight ambulatory patients with congestive cardiac failure took part in a double-blind clinical trial of 50 mg hydrochlorothiazide orally daily and slow-release formulation of 60 mg furosemide orally daily. Following a one-week period of placebo administration, patients were randomly allocated to the treatment w...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1982.tb02644.x

    authors: Vermeulen A,Chadha DR

    更新日期:1982-11-01 00:00:00

  • Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers.

    abstract::The pharmacokinetics (PK), pharmacodynamics (PD), and safety of a platelet GPIIb/IIIa receptor antagonist, RGD891, and its active metabolite, RGD039, were evaluated after administration of various intravenous regimens of RGD891 to healthy male volunteers in two Phase I studies. Plasma and urine concentrations of RGD89...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Zannikos PN,Rohatagi S,Jensen BK,DePhillips SL,Massignon D,Calic F,Sibille M,Kirkesseli S

    更新日期:2000-11-01 00:00:00

  • Food effect on bioavailability of modified-release trimetazidine tablets.

    abstract::This study aimed to investigate a food effect on the bio-availability of modified-release (MR) trimetazidine tablets in 36 healthy volunteers. Trimetazidine, an anti-ischemic drug, protects the myocardial cell from the harmful effects of ischemia. The authors investigated the effect of being under a fasting or fed sta...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270011422813

    authors: Ozbay L,Unal DO,Erol D

    更新日期:2012-10-01 00:00:00